E-LIB Suche - Ergebnisse für: Leslie, Lori

1

Subsequent Malignancies After CD19-Targeted Chimeric Antige..:

Lorenc, Rachel ; Shouval, Roni ; Flynn, Jessica R....
Transplantation and Cellular Therapy. , 2024

Link: https://doi.org/10.1016/..

2

Three-year follow-up analysis of axicabtagene ciloleucel in..:

Neelapu, Sattva S. ; Chavez, Julio C. ; Sehgal, Alison R....
Blood. 143 (2024) 6 - p. 496-506 , 2024

Link: https://doi.org/10.1182/..

3

Brentuximab vedotin plus cyclophosphamide, doxorubicin, eto..:

Herrera, Alex F ; Zain, Jasmine ; Savage, Kerry J...
The Lancet Haematology. , 2024

Link: https://doi.org/10.1016/..

4

Anti-CD19 chimeric antigen receptor T-cell therapy has less..:

Benjamini, Ohad ; Fried, Shalev ; Shouval, Roni...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

5

Treatment Discontinuation Patterns for Patients With Chroni..:

Shadman, Mazyar ; Manzoor, Beenish S. ; Sail, Kavita...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 7 - p. 515-526 , 2023

Link: https://doi.org/10.1016/..

6

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS A..:

Rhodes, Joanna ; Shadman, Mazyar ; Lamanna, Nicole...
HemaSphere. 7 (2023) S3 - p. e96103aa , 2023

Link: https://doi.org/10.1097/..

7

Phase 1b dose-finding study of rituximab, lenalidomide, and..:

Ip, Andrew ; Petrillo, Alessandra ; Della Pia, Alexandra...
Leukemia & Lymphoma. 64 (2023) 14 - p. 2225-2235 , 2023

Link: https://doi.org/10.1080/..

8

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CH..:

Lansigan, Frederick ; A. Eyre, Toby ; Ghosh, Nilanjan...
HemaSphere. 7 (2023) S3 - p. e6855326 , 2023

Link: https://doi.org/10.1097/..

9

3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axi..:

Neelapu, Sattva S. ; Chavez, Julio C. ; Sehgal, Alison R....
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S374 , 2023

Link: https://doi.org/10.1016/..

10

PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY O..:

Leslie, Lori ; Tees, Michael ; Flinn, Ian W....
HemaSphere. 7 (2023) S3 - p. e50042ff , 2023

Link: https://doi.org/10.1097/..

11

Identifying an optimal fludarabine exposure for improved ou..:

Scordo, Michael ; Flynn, Jessica R. ; Gonen, Mithat...
Blood Advances. 7 (2023) 18 - p. 5579-5585 , 2023

Link: https://doi.org/10.1182/..

12

Safety and Efficacy of Axicabtagene Ciloleucel versus Stand..:

Westin, Jason R. ; Locke, Frederick L. ; Dickinson, Michael...
Clinical Cancer Research. 29 (2023) 10 - p. 1894-1905 , 2023

Link: https://doi.org/10.1158/..

13

Outcomes among adult recipients of CD19 CAR T-cell therapy ..:

Samples, Laura ; Sadrzadeh, Hossein ; Frigault, Matthew...
International Journal of Cancer Care and Delivery. 3 (2023) Supplement 2 - p. , 2023

Link: https://doi.org/10.53876..

14

Real-world Clinical Outcomes of First-Line Ibrutinib or Che..:

Huang, Qing ; Deering, Kathleen L. ; Harshaw, Qing.
Advances in Therapy. 39 (2022) 7 - p. 3292-3307 , 2022

Link: https://doi.org/10.1007/..

15

Venetoclax retreatment of patients with chronic lymphocytic..:

Thompson, Meghan C. ; Harrup, Rosemary A. ; Coombs, Catherine C....
Blood Advances. 6 (2022) 15 - p. 4553-4557 , 2022

Link: https://doi.org/10.1182/..